Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC, 3800, Australia.
Faculty of Natural and Agricultural Sciences, Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, 0028, South Africa.
Commun Biol. 2020 Nov 20;3(1):701. doi: 10.1038/s42003-020-01424-z.
Mitosis has been validated by numerous anti-cancer drugs as being a druggable process, and selective inhibition of parasite proliferation provides an obvious opportunity for therapeutic intervention against malaria. Mitosis is controlled through the interplay between several protein kinases and phosphatases. We show here that inhibitors of human mitotic kinases belonging to the Aurora family inhibit P. falciparum proliferation in vitro with various potencies, and that a genetic selection for mutant parasites resistant to one of the drugs, Hesperadin, identifies a resistance mechanism mediated by a member of a different kinase family, PfNek1 (PF3D7_1228300). Intriguingly, loss of PfNek1 catalytic activity provides protection against drug action. This points to an undescribed functional interaction between Ark and Nek kinases and shows that existing inhibitors can be used to validate additional essential and druggable kinase functions in the parasite.
有许多抗癌药物已经证实有丝分裂是一个可靶向的过程,选择性抑制寄生虫的增殖为治疗疟疾提供了一个明显的治疗干预机会。有丝分裂是通过几种蛋白激酶和磷酸酶的相互作用来控制的。我们在这里表明,属于 Aurora 家族的人类有丝分裂激酶抑制剂以不同的效力抑制体外疟原虫的增殖,并且对一种药物 Hesperadin 具有抗性的突变体寄生虫的遗传选择鉴定出一种由不同激酶家族成员 PfNek1 (PF3D7_1228300) 介导的抗性机制。有趣的是,PfNek1 催化活性的丧失为药物作用提供了保护。这表明 Ark 和 Nek 激酶之间存在未描述的功能相互作用,并表明现有的抑制剂可用于验证寄生虫中其他必需的和可靶向的激酶功能。